Bausch + Lomb, Corporation
https://www.bausch.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bausch + Lomb, Corporation
IPO Numbers Dipped In 2023, But 2024 Is Off To A Good Start
There were 21 biopharma initial public offerings in 2023, including J&J’s consumer health spin-out Kenvue, versus 22 in 2022. However, IPO proceeds are rising in 2024.
Contaminated Eye Drops Return To US FDA’s View
FDA says FivFivGo, Rebright and South Moon are copycats in packaging easily mistaken for Lumify OTC eye drops. Testing found South Moon contaminated with bacteria linked to an antibiotic-resistant infection; agency warns using any of the three poses risk of eye infection.
US Q4 Consumer Health Earnings Preview: Supply Chain Disruption Returns, Opill Launch Waits
Attacks on shipping since November in the Red Sea lead shipping lines to re-route vessels south of Africa, spiking shipping costs. Perrigo began 2024 saying it expects sales of Opill oral contraceptive to start early in the first quarter, but now expects to start late in the quarter.
Beauty Part Of Lumify Story For Bausch + Lomb? From Redness Relief To 'Make Eyes Look Beautiful'
Lumify sales up 47% to reported $44m in Q3 as brand and firm’s vision health vitamins Ocuvite and PreserVision remain key drivers for its vision care segment, which also includes contact lenses and solutions.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice